Long-term survival without graft-versus-host-disease following infusion of allogeneic myeloma-specific Vβ T cell families

BACKGROUND: Despite chemo-induction therapy and autologous stem cell transplantation (ASCT), the vast majority of patients with Multiple Myeloma (MM) relapse within 7 years and the disease remains incurable. Adoptive Allogeneic T-cell therapy (ATCT) might be curative for MM, however current ATCT pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yado, S., Luboshits, G., Hazan, O., Or, R., Firer, M. A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854718/
https://www.ncbi.nlm.nih.gov/pubmed/31727148
http://dx.doi.org/10.1186/s40425-019-0776-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6854718/
https://www.ncbi.nlm.nih.gov/pubmed/31727148
http://dx.doi.org/10.1186/s40425-019-0776-9

Ejemplares similares